title: Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients.
abstract: BACKGROUND
  Hyperhomocysteinemia may constitute an independent risk factor for cardiovascular disease and may promote atherothrombosis. Psoriasis is one of the diseases associated with increased atherothrombosis. The aim of the present study was to examine serum total homocysteine (tHcy) level and its relationships with atherothrombotic markers.
  
  
  METHODS
  The study group included 30 patients with psoriasis (17 females and 13 males) with a mean age of 34.2 (age range: 27-40) and 30 sex and age matched healthy volunteers (15 females and 15 males) with a mean age of 36.7 (age range: 26-48). The concentrations of lipids, lipoproteins, acute phase reactants, tHcy and atherothrombotic markers [fibronectin, soluble vascular adhesion molecules-1 (sVCAM-1), soluble intercellular adhesion molecules-1 (sICAM-1), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), autoantibodies against oxidized LDL (AuAb-oxLDL)] were determined.
  
  
  RESULTS
  The mean levels of serum tHcy, fibrinogen, fibronectin, sICAM, PAI-1 and AuAb-oxLDL were increased in patients whereas tPA, vitamin B(12) and folate levels were decreased significantly. Increased levels of sVCAM were not statistically significant. tHcy levels were negatively correlated with vitamin B(12) (r=-0.40, P=0.027) and positively correlated with PAI-1 and AuAb-oxLDL levels (r=0.46, P=0.011; r=0.39, P=0.035, respectively).
  
  
  CONCLUSIONS
  It was concluded that the increased homocysteine concentration and altered endothelial cell-mediated proteins associated with increased lipids and LDL oxidation may play an important role for the development of atherothrombotic complications with psoriasis.
authors.affiliation: Faculty of Medicine, Department of Biochemistry, Karadeniz Technical University, Turkey.
authors.forename: Birgül
authors.initials: B
authors.lastname: Vanizor Kural
authors.forename: Asim
authors.initials: A
authors.lastname: Orem
authors.forename: Gülseren
authors.initials: G
authors.lastname: Cimşit
authors.forename: Hüseyin Avni
authors.initials: HA
authors.lastname: Uydu
authors.forename: Yunus Emre
authors.initials: YE
authors.lastname: Yandi
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alver
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis; D000328:Adult; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology / Q000378:metabolism*; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005353:Fibronectins / Q000097:blood; D005492:Folic Acid / Q000097:blood; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011565:Psoriasis / Q000097:blood / Q000150:complications / Q000378:metabolism*; D013927:Thrombosis / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000097:blood; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D000209:Acute-Phase Proteins; D001323:Autoantibodies; D015415:Biomarkers; D005353:Fibronectins; D008077:Lipoproteins, LDL; D017395:Plasminogen Activator Inhibitor 1; C099252:oxidized low density lipoprotein; D006710:Homocysteine; D005340:Fibrinogen; D005492:Folic Acid; D010959:Tissue Plasminogen Activator; D014805:Vitamin B 12